Why is multi-modal profiling necessary? Can't standard whole-exome sequencing (WES) detect TSG loss?

Standard WES is excellent for point mutations, but it often misses the "silent killers" - TSGs inactivated solely by promoter hypermethylation or complete loss of an allele. Our integrated approach is necessary because a TSG like BRCA1 might appear structurally normal in WES but be functionally silenced by epigenetic modification.

How does Creative Biolabs' TSG Functional Status Score help me prioritize targets?

The Score is a comprehensive metric that weighs the severity and type of inactivation. It provides a clear, quantitative measure of the overall oncogenic drive from TSG loss, allowing your team to rapidly prioritize targets with the highest therapeutic leverage.

Tumor Suppressor Gene Profiling Services

The tumor suppressor gene profiling services offered by Creative Biolabs provide research institutions and pharmaceutical developers with a comprehensive, multi-omic assessment of tumor suppressor gene inactivation mechanisms. This advanced platform integrates diverse data streams - specifically genetic alterations, epigenetic silencing, and structural loss, such as Loss of Heterozygosity (LOH) - to yield a definitive TSG functional status score, thereby facilitating confident target identification. This rigorous approach affords users superior insights into synthetic lethal dependencies and actionable epigenetic vulnerabilities, which consequently accelerate preclinical validation and the optimization of rational therapeutic design strategies.

Comprehensive Functional Mapping of Tumor Suppressor Gene

Tumor suppressor gene profiling services (TSG Profiling) analyze the multi-faceted inactivation of the cell's "brakes," moving beyond simple sequencing to capture the full spectrum of loss-of-function events. The inactivation of TSGs is fundamental to cancer research, as evidenced by the Knudson two-hit hypothesis and early MMCT functional studies. Our service integrates next-generation sequencing with epigenetic and structural analyses to definitively map the functional status of these critical genes, accelerating the identification of synthetic lethal targets and paving the way for effective oncology research strategies.

Fig 1. Double effect of tumor suppressor genes in schizophrenia. (OA Literature)

Fig.1 A working model for the double-edged effects of tumor suppressor genes on both cancer and schizophrenia (SCZ) risk. ¹

What We Can Offer

Tumor Suppressor Gene Loss & Inactivation Analysis Service

This core offering focuses on utilizing deep-coverage targeted sequencing to accurately identify small variations, such as point mutations and indels, within the critical coding and splice regions of key tumor suppressor genes.

Learn More →

Tumor Suppressor Gene Methylation & Epigenetic Silencing Profiling Service

This service quantitatively assesses the methylation status of promoter CpG islands associated with tumor suppressor genes. This analysis is crucial for detecting the widespread transcriptional silencing mechanisms often observed in regulatory pathways.

Learn More →

Tumor Suppressor Chromatin Accessibility & Enhancer Activity Analysis Service

This analysis involves examining open chromatin regions and histone modification patterns around critical genes. The objective is to identify dysregulated enhancer elements that influence the expression levels of both tumor suppressors and oncogenes.

Learn More →

Loss of Heterozygosity & Allelic Imbalance Analysis Service

High-resolution Copy Number Variation mapping is employed to precisely detect structural deletions and chromosome loss. These alterations collectively represent the frequent secondary genetic event integral to complete tumor suppressor inactivation.

Learn More →

Functional Validation of Tumor Suppressor Genes Screening Service

This specialized service confirms the therapeutic dependencies created by profiled tumor suppressor gene loss. It utilizes established genetic perturbation tools in appropriate cellular models.

Learn More →

Strategic Contribution of Creative Biolabs' Tumor Suppressor Gene Profiling Services

Highlights

Multi-Modal Resolution

We are one of the few providers that integrate SNV, LOH/CNV, and promoter methylation data streams to deliver a single, definitive TSG functional status score, ensuring 100% functional TSG status resolution.

Addressing the Epigenetic Paradox

We specifically target and quantify the complex epigenetic network (methylation, histone modifications) that silences TSGs like BRCA1 and CDKN2A, which is critical for identifying targets for reversible epigenetic strategies.

Unparalleled Heterogeneity Capture

Our high-resolution CNV mapping and proprietary algorithms are designed to detect subclonal TSG losses within heterogeneous tumor populations, crucial for accurate prognosis and drug resistance mechanism prediction.

Validated Science

Our methodology is rooted in the foundational principles of cancer genetics, including the Knudson two-hit hypothesis, and validated against the functional complementation insights established.

To initiate collaboration, kindly request a comprehensive quotation for the Creative Biolabs service advantage.

Customer Reviews

FAQs

Related Services

Multi-omic Analyses

For projects requiring ultimate resolution, transition from bulk profiling to single-cell analysis to map TSG status within specific tumor cell subtypes and immune microenvironment populations.

Learn More →

Small Molecules for Ferroptosis-based Cancer Therapy Research

Focuses on the regulated cell death pathway of ferroptosis, which is often influenced by TSG loss. This service identifies vulnerabilities for small molecule-based ferroptosis inducers to treat tumors resistant to conventional therapies.

Learn More →

How to Contact Us

Creative Biolabs' tumor suppressor gene profiling services provide the requisite molecular depth and contextual insight necessary to advance the next generation of oncology therapeutics. This commitment ensures the delivery of actionable, scientifically validated data capable of addressing the inherent complexity of cancer genetics.

Engage with our team to request comprehensive information and initiate a discussion regarding your specific research objectives.